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ABSTRACT 
Background:  Impairment in instrumental activities of daily living (IADL) begins 
as individuals with amnestic mild cognitive impairment (MCI) transition to Alzheimer‟s 
disease (AD) dementia.  IADL impairment in AD dementia has been associated with 
inferior parietal, inferior temporal, and superior occipital hypometabolism using 18F-
fluorodeoxyglucose (FDG) positron emission tomography (PET).   
Objective: The objective of this study was to investigate the relationship between 
regional cerebral FDG metabolism and IADL cross-sectionally and longitudinally in 
clinically normal (CN) elderly, MCI, and mild AD dementia subjects. 
Methods: Four hundred and two subjects (104 CN, 203 MCI, 95 AD dementia) 
participating in the Alzheimer‟s Disease Neuroimaging Initiative at academic centers 
across North America underwent clinical assessments every 6 to 12 months for up to 3 
years and FDG-PET at their baseline visits.  The subjective informant-based Functional 
Activities Questionnaire (FAQ) was used to assess IADL.  Data reduction analyses were 
first conducted to reduce 35 FDG regions to 6 regions that significantly associated with 
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total FAQ score after adjusting for multiple tests.  These 6 FDG regions were then 
entered into a general linear model with backward elimination (p<0.05) assessing their 
cross-sectional relation to baseline FAQ and a mixed random and fixed coefficient linear 
longitudinal regression model assessing their relation to FAQ over time.  Analyses 
included the following covariates: diagnosis, demographics, Apolipoprotein E4 (ApoE4) 
carrier status, memory and executive function, and behavioral factors.  
Results:  The cross-sectional analysis showed that middle frontal (p=0.003) and 
orbitofrontal hypometabolism (p=0.009) were significantly associated with greater IADL 
impairment.  Additionally, the interaction of diagnosis with posterior cingulate 
(p<0.0001) and with parahippocampal hypometabolism (p=0.0008) showed a steeper 
decline in IADL performance as FDG metabolism decreased for the AD dementia group 
relative to the MCI group, and the MCI group relative to the CN group.  The longitudinal 
analysis showed that baseline middle frontal (p=0.0005) and posterior cingulate 
hypometabolism (p=0.004) were significantly associated with greater rate of increase in 
IADL impairment over time. 
Conclusions:  These results suggest that frontal and medial parietal synaptic 
dysfunction relates to functional decline at baseline and over time across the AD 
spectrum independent of demographics, APOE4 carrier status, memory and executive 
function performance, and behavioral factors. 
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GLOSSARY 
AC-PC line - A reference line used in brain imaging that extends from the superior 
surface of the anterior commissure to the center of the posterior commissure of the brain 
(http://airto.ccn.ucla.edu/BMCweb/HowTo/AC-PC.html; Tailarach, 1988). 
ANCOVA - The analysis of covariance is used to analyze data with a continuous 
numeric dependent variable and one or more categorical or discrete predictor variables 
with the optional inclusion of some continuous numeric „covariates‟ whose linear or 
nonlinear relations to the dependent variable are statistically discrete from other predictor 
variable effects (Locascio and Atri, 2011).   
Bonferroni correction - A simpler, slightly more conservative approximation of the 
Sidak correction for multiple comparisons, in which obtained p values are multiplied by 
n.  Conversely, the significance cutoff can be equivalently divided by n. (Kleinbaum, 
2008; Myers, 1979; Locascio et al., 1997). 
Homoscedasticity - This assumption also called homogeneity of variance states that the 
variance of any dependent variable Y has the same finite value for any independent 
variable of X (Kleinbaum et al., 2008). 
Multicollinearity - The assumption occurs when one independent variable is a linear 
function of other independent variables in a statistical regression model (Monti, 2011). 
Sidak correction - A p value adjustment for multiple comparisons that assumes 
independence of n significance tests each with a type I error rate of a, and a greater 
probability of yielding significant results under a global null hypothesis if all the tests are 
perfectly positively correlated (Šidák, 1967; Locascio et al., 1997). 
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INTRODUCTION 
The rapid growth of the aging population in the United States has fueled the rising 
prevalence of Alzheimer‟s disease (AD) dementia now endemic to this demographic.  
Currently, AD dementia is estimated to affect nearly 1 out of 10 individuals over the age 
of 65.  The multi-staged disease is believed to transition from clinically normal (CN) with 
evidence of underlying AD pathology, representing preclinical AD, to mild cognitive 
impairment (MCI), followed by an ultimate decline towards dementia (Sperling et al., 
2011).  
As AD progresses, patients experience worsening symptoms, including episodic 
memory impairment, other cognitive deficits, mood and behavioral changes, and 
impaired daily functioning (Marshall et al., 2011; Vidoni et al., 2010).  These symptoms 
greatly compromise an individual‟s quality of life, but perhaps none more than impaired 
daily functioning.  Daily functioning is measured by performance of activities of daily 
living (ADL), impairment in which is integral for the diagnosis of AD dementia.  These 
patients experience an early loss of independence, which increases the burden of 
responsibilities on patient caregivers.  ADL are categorized as either basic or 
instrumental with the former including eating, grooming, bathing, dressing and toileting, 
while the latter is comprised of more complex tasks such as managing one‟s own 
schedule, performing household chores like cleaning and preparing meals, handling 
finances, driving or using public transportation and shopping (Marshall et al., 2012).  
Impaired ADL also play a significant role in understanding disease progression.  
While impairment in basic ADL is found in the moderate-to-severe stage of AD 
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dementia, decline in instrumental ADL (IADL) has been found to accompany the earlier 
transition from the MCI stage to AD dementia (Tabert et al, 2002; Luck et al., 2011; 
Marshall et al., 2011).  This feature of IADL impairment is of particular importance 
given disappointing results from recent AD clinical trials, which indicated the need for 
earlier intervention in order to slow disease progression and improve treatment outcomes 
(Sperling, et al., 2011).   
Clinicians use functional assessment scales to detect the changes in IADL 
impairment that occur throughout the course of AD.  These scales are administered with 
either caregivers (informant-based) or patients (self-reported), and are typically 
subjective or performance-based.  The Functional Assessment Questionnaire (FAQ) 
(Pfeffer et al., 1982) is a ten-item subjective, informant-based scale primarily used to 
detect IADL impairment in MCI and mild dementia (Marshall et al., 2012).  Recently, 
two large multicenter studies established that the FAQ clearly distinguishes between the 
three stages of AD progression; CN, MCI and AD dementia (Marshall et al., 2011; 
Morris, 2012).  
IADL impairment has also been associated with changes in brain metabolism as 
measured by positron emission tomography (PET).  Using radio-labeled glucose, 
18
F-2-
fluoro-2-deoxy-D-glucose (FDG) as a metabolic detection agent, Landau et al. 
demonstrated an association between FDG hypometabolism in a composite of brain 
regions typically implicated in AD (temporal, lateral parietal and posterior cingulate 
cortices), and greater IADL impairment in a longitudinal study in MCI and mild AD 
dementia subjects (Landau et al., 2011).  Cross-sectional analyses have also been 
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conducted to localize IADL impairment to specific brain regions.  One such study 
revealed an association between IADL impairment and decreased regional glucose 
metabolism in the inferior parietal, superior occipital, and inferior temporal cortices in 
AD dementia (Salmon et al., 2005). 
Loss of independence in AD dementia patients due to disease progression is a 
significant challenge faced by both patients and their caregivers and is attributable to 
impaired IADL and later basic ADL performance.  Measurement of IADL impairment 
with the FAQ scale and the associated synaptic dysfunction seen on FDG-PET, have 
demonstrated the utility of IADL in tracking disease progression, a critical step for 
improving treatment outcomes in AD clinical trials. 
The objective of this study was to investigate the relationship between cerebral 
glucose metabolism in FDG-PET regions of interest (ROIs) and IADL as measured by 
FAQ both cross-sectionally and longitudinally across the AD continuum (CN, MCI, and 
mild AD dementia), while controlling for subject demographics, diagnosis, behavioral 
changes, and cognitive performance. 
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METHODS 
Subjects 
 This study analyzed data acquired from the Alzheimer‟s Disease Neuroimaging 
Initiative (ADNI) database (www.loni.ucla.edu\ADNI) (Weiner et al., 2012). ADNI is a 
multi-center, observational trial that follows CN, amnestic MCI, and mild AD dementia 
subjects recruited from the United States and Canada.  Subjects undergo longitudinal 
clinical and neuropsychological assessments, multi-modal neuroimaging, and biomarker 
assays. ADNI aims to establish a large dataset further characterizing the stages of disease 
progression and to determine reliable biomarkers and standardized brain imaging 
techniques for use in treatment outcomes of AD clinical trials.  ADNI has been made 
possible by the collaborative efforts of co-investigators from numerous academic 
institutions and private corporations across North America (Weiner et al., 2012). 
 Four hundred and two subjects underwent clinical assessments every 6 to 12 
months up to 3 years including baseline FDG PET in the ADNI study (diagnoses at 
baseline: 104 CN, 203 amnestic MCI, 95 AD dementia) and were selected as previously 
described (Marshall et al., 2011).  At screening, subjects were ages 55-91 (inclusive), 
were medically stable and in generally good health, did not have significant neurological 
conditions, and had a study partner able to provide collateral information about the 
subject‟s daily functioning, cognition, and behavior. Subjects did not have significant 
cerebrovascular disease and had a Modified Hachinski Ischemic Score (Rosen et al., 
1980) ≤ 4. Subjects did not have active psychiatric disorders and had a Geriatric 
Depression Scale, short form (Sheikh et al., 1986) ≤ 5. 
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Subjects were assigned to diagnostic groups (CN, amnestic MCI, mild AD 
dementia) as determined by site investigators at screening and baseline visits.  Briefly, 
CN subjects had a global Clinical Dementia Rating (CDR) (Morris, 1993) score of 0, a 
Mini-Mental State Examination (MMSE) (Folstein et al., 1975) score of 25-30 
(inclusive), intact IADL, and demonstrated an absence of significant memory impairment 
by performance within 1.5 standard deviations of education adjusted cut-off scores on the 
delayed recall portion of one Logical Memory story (LM-IIa) of the Wechsler Memory 
Scale-Revised (WMS-R)  (Weschler, 1987).  Amnestic MCI subjects had a CDR global 
score of 0.5 and memory box score ≥ 0.5, MMSE score of 24-30 (inclusive), a self-
reported or informant-based memory complaint, objective memory loss on the WMS-R 
LM-IIa, essentially preserved IADL (based on qualitative determination of clinical 
judgment by the site investigator), and were not demented. Mild AD dementia subjects 
had a CDR global score of 0.5 or 1.0, MMSE score of 20-26 (inclusive), and met the 
National Institute of Neurologic and Communicative Disorders and Stroke and the AD 
and Related Disorders Association Work Group (NINCDS/ADRDA) criteria for probable 
AD (McKhann et al., 1984).   
The study was approved by the Institutional Review Board (IRB) of each 
participating site. Written informed consent was obtained from all subjects and study 
partners prior to initiation of any study procedures in accordance with local IRB 
guidelines. 
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Clinical Assessments 
 Clinical assessments were performed as previously described (Marshall et al., 
2011).  IADL were assessed with the FAQ, which consists of 10 items where higher 
scores indicate greater impairment; the score range for each item is 0-3. The sum of the 
scores of the 10 items, a total FAQ score, was used in the current analyses (range 0-30). 
There is no established cut-off score for impairment on the FAQ. However, one study 
reported that a score of ≥ 6 is suggestive of functional impairment (Nitrini et al., 2004).  
Other assessments used in this study included: the Rey Auditory Verbal Learning 
Test (RAVLT) (Rey, 1964) total learning score, which measures episodic memory 
performance with lower scores indicating greater impairment (range 0-75); the Wechsler 
Adult Intelligence Scale-Revised Digit Symbol (Weschler, 1981), which measures 
processing speed, working memory, and visual scanning with lower scores indicating 
greater impairment (range 0-110); the Neuropsychiatric Inventory brief questionnaire 
form (NPI-Q)  (Kaufer, 2000) apathy and depression items, which measure apathy and 
depression with higher scores indicating greater mood disturbance (range 0-3); the 
American National Adult Reading Test (AMNART) intelligence quotient (IQ) (Nelson, 
1978), which estimates premorbid verbal IQ (VIQ) and can serve as a proxy of cognitive 
reserve with higher scores indicate higher premorbid intelligence (range 74-132). 
Apolipoprotein E4 (APOE4) carrier status (homozygous carrier, heterozygous 
carrier, or non-carrier) was reported for subjects, while duration of AD symptoms (in 
years) was reported only for those subjects with a diagnosis of mild AD dementia at 
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screening.  Duration of AD symptoms was noted as zero for CN and MCI subjects 
(Marshall, 2011). 
 
FDG PET Data 
FDG PET images were acquired for subjects using multiple scanners in locations 
throughout the United States.  Images were acquired within 30-60 minutes of injection of 
the FDG imaging agent and were scanned using either static or dynamic methods.  
Dynamic scans involved the acquisition of six frames that were averaged to yield a single 
representative image, while static scanned, single-frame images were averaged and 
standardized to an imaging grid about the anterior commissure - posterior commissure 
(AC-PC) line.  All acquired images were scaled using a subject-specific intensity 
normalization mask to control for differences in scan intensity attributed by the use of 
multiple scanners.  The images were filtered for uniform resolution before smoothing and 
final processing (Landau et al., 2011).  Full details of FDG PET data acquisition ADNI 
protocol are available to the public on the UCLA Laboratory of Neuroimaging website 
(http://www.loni.ucla.edu/ADNI/Data?ADNI_Data.shtml).  
 
FDG ROI Generation & Selection 
 Cortical FDG metabolism was expressed as the standardized uptake value (SUV) 
and normalized to an aggregate of cerebellar grey, pons, and primary cortex for each 
ROI. These regions were sampled using the Harvard-Oxford probabilistic atlas 
(http://neuro.debian.net/pkgs/fsl-harvard-oxford-atlases.html; Frazier et al., 2005;  
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Desikan et al., 2006; Makris et al., 2006; Goldstein et al., 2007).  Thirty-five bilateral 
cortical ROIs were used in the preliminary analyses, which were reduced to six ROIs that 
significantly associated with total FAQ score.  These six ROIs were used in the main 
cross-sectional and longitudinal analyses and are depicted in Figure 2.  
 
Statistical Analyses 
All analyses performed in this study were run using SAS Version 9.3 and JMP 
Version Pro 10 statistical and graphical software.  Associations between diagnostic 
groups and subject demographics and characteristics were evaluated using analysis of 
variance (ANOVA) with the Tukey post hoc test for continuous variables and the Pearson 
chi-square test for categorical variables. 
Preliminary Multiple Test Protection and Data Reduction Screening Tests 
Using a preliminary multivariate approach, separate analyses of covariance 
(ANCOVA) were run for each of the thirty-five respective FDG ROIs in determining p 
values and as a data reduction method.  The main effect of diagnosis at baseline with a 
covariate of the given FDG ROI was included in the model with the total baseline FAQ 
score serving as the dependent variable.  Only the MCI and AD groups were included 
because of the floor effect for the CN population (Marshall et al., 2011).  The thirty-five 
resulting p values for each respective FDG ROI were then adjusted for using the 
stepdown Sidak correction method (Šidák, 1967; Finner, 1993).  This method assumes 
the tests are independent despite the inter-correlations of the FDG ROIs and adjusts p 
values for the number of significance tests while treating each result as a separate 
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univariate test in which the given FDG ROI was not adjusted for relations with other 
FDG ROIs.  It provides a conservative protection that subsequent multiple tests are not 
chance effects.   
To further reduce the data, a general linear model (GLM) regressing the baseline 
FAQ score on baseline diagnosis (excluding the CN population) including all thirty-five 
FDG ROIs as covariates was run with backward elimination using a 0.05 alpha cutoff for 
inclusion of terms.  This method is the converse of the previously employed Sidak 
correction as it adjusts each FAQ versus FDG ROI relation for its relations to all other 
FDG ROIs included in the model.  However, it does not adjust p values for multiple test 
chance effects (Šidák 1967 and Myers 1979).  The FDG ROIs significantly associated 
with total baseline FAQ were used in the main cross-sectional and longitudinal mixed 
effects models. 
Cross Sectional Analyses 
The six FDG ROI surviving the backward elimination approach above were then 
entered as simultaneous covariates in another backward elimination GLM (with a cutoff 
of 0.05) regressing baseline FAQ on these covariate as well as diagnosis (including CN), 
and the interaction of each of these FDG ROIs with diagnosis.  Additional factors and 
covariates serving as initial predictors included sex, the interaction of sex and diagnosis, 
baseline age (linear and quadratic terms), duration of AD dementia symptoms (set to 
mean zero with slight random error for MCI and CN), RAVLT total learning, Digit 
Symbol, the NPI-Q apathy and depression items, the number of APOE4 alleles, and VIQ.  
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Significance test results (p values) were complemented with effect size estimates such as 
partial regression coefficient estimates () with confidence intervals (CI), covariate 
adjusted means and estimates of percent variance accounted for in the dependent variable 
uniquely by individual predictors, as well as by  the model as a whole (R
2
).  Residuals 
from the final model were checked for conformance to assumptions of normality and 
homoscedasticity. 
Longitudinal Analyses 
A mixed effect longitudinal analysis analogous to the cross sectional analysis 
above was run with FAQ as the dependent variable and including the same covariates as 
described for the cross-sectional model, a random intercept and linear effect of years in 
the study, as well as a baseline FAQ covariate and its interaction with time, the 
interaction of diagnosis with time, and the separate interactions of the six significant FDG 
ROIs with time.  Random intercepts and slope terms for time were initially allowed to be 
correlated, and then all fixed and random covariance terms were subjected to backward 
elimination at a cutoff of 0.05.  Residuals from the full mixed fixed and random term 
model were also checked for conformance to assumptions of normality and 
homoscedasticity.    
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RESULTS 
Table 1 provides baseline demographic and clinical data for all subjects and for 
each of the three diagnostic groups (CN, MCI, mild AD dementia).  There were 
significant differences between diagnostic groups for all variables in expected directions 
except for age and sex, which was similar across all groups.  Table 2 summarizes the 
longitudinal data for FAQ scores collected over the three-year study duration; this is 
further illustrated by diagnostic group in Figure 1. 
 
Preliminary Multiple Test Protection and Data Reduction Screening Tests 
The thirty-five univariate ANCOVAs illustrated the expected negative relations of 
baseline FAQ with each of the thirty-five FDG ROI (higher FAQ score indicating greater 
IADL impairment was associated with decreased metabolism), of which twenty-seven 
were statistically significant at p<0.05 with twenty-five of these remaining significant 
after applying the Sidak correction.  This demonstrated widespread, real within 
diagnostic group negative relations of individual FDG ROI to total baseline FAQ 
univariately, and any reported significant relations are therefore not likely chance effects 
related to multiple testing.   
 The backward elimination GLM of the total baseline FAQ regressed on all thirty-
five FDG ROI simultaneously with initial predictors, along with baseline diagnosis, 
reduced down to six FDG ROI that significantly associated with total FAQ score and 
demonstrated an additive significant diagnosis effect (AD FAQ mean > MCI mean).  The 
FDG ROI surviving backward elimination were the posterior cingulate gyrus, 
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orbitofrontal cortex, frontal pole, lingual gyrus, middle frontal gyrus, and 
parahippocampal gyrus.  All regions showed expected negative relations with total 
baseline FAQ partialed from the relations to other FDG-ROI except for the frontal pole 
and lingual gyrus, whose counterintuitive positive partialed relations may have been due 
to multicollinearity.  The two regions, especially frontal pole, demonstrated moderate to 
high positive correlations with the other FDG ROI in the model.  Moreover, the 
unadjusted univariate relation of these two regions to FAQ was negative (frontal pole: r=-
0.27, p<0.0001; lingual gyrus: r=-0.10, p=0.08).  This suggests that the true relation of 
these two regions with FAQ is negative similarly to the other regions and that the 
multicollinearity within the multivariate model led to the counterintuitive positive 
relation.  Table 3 summarizes the results for the six FDG ROI surviving the backward 
elimination GLM analysis.  The model as a whole accounted for 60 percent of the 
variance of FAQ.  Figure 2 illustrates the location of these ROI in the brain. 
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Table 1. Baseline demographic and characteristics of subjects. 
 
AD (Alzheimer‟s disease), AMNART VIQ (American National Adult Reading Test verbal intelligence 
quotient), APOE4 (Apolipoprotein E4), CN (clinically normal elderly), FAQ (Functional Activities 
Questionnaire), MCI (mild cognitive impairment), MMSE (Mini-Mental State Examination), NPI-Q 
(Neuropsychiatric Inventory brief questionnaire form), RAVLT (Rey Auditory Verbal Learning Test). 
 
All values (except n, sex, APOE4) represent mean ± standard deviation. 
*p<0.0001 for CN vs. MCI, CN vs. AD and MCI vs. AD. 
† p<0.01 for CN vs. MCI, CN vs. AD and MCI vs. AD. 
††p<0.05 for CN vs. MCI, CN vs. AD and MCI vs. AD. 
‡p<0.001 for CN vs. AD and MCI vs. AD. 
‡‡p<0.01 for CN vs. MCI and MCI vs. AD. 
 
 
Group All subjects CN MCI AD dementia 
N 402 104 203 95 
Age (years) 75.4±6.7 75.9±4.8  75.0.±7.2  75.7±7.4  
Sex (% male) 63.9 62.0 67.5  59.0 
Education (years) 15.5±3.1‡ 15.9±3.1  15.8±2.9  14.6±3.3  
AMNART VIQ 117.5±11.5† 120.7±11.29 117.2 ±11.0 114.4±11.9 
Duration of AD symptoms 
(years) 
- 0 0 3.7±2.4 
APOE4  
(% non-carrier/ 
heterozygous carrier/ 
homozygous carrier) 
51.0/38.3/ 
10.7* 
75.0/23.1/ 
1.9 
46.8/40.4/ 
12.8  
33.7/50.5/ 
15.8 
MMSE 26.8±2.6* 29.0±1.1 27.2±1.7 23.5±2.1 
RAVLT Total Learning 32.2±11.1* 42.2±9.8 31.4±9.1 22.9±6.9 
Digit Symbol 36.5±13.0*  44.5±10.4 37.4±10.9 26.0±12.4  
NPI-Q Apathy  
(% present) 
0.3±0.6 (18.2)* 0.02±0.1 (1.9) 0.2±0.6 (15.3) 0.6±0.8 (42.1) 
NPI-Q Depression  
(% present) 
0.2±0.5 (18.7)* 0.1±0.3 (6.7) 0.2±0.5 (17.2) 0.4±0.7 (34.7) 
FAQ 5.0±6.6* 0.2±0.8 3.4±3.9 13.6±6.7 
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Table 2. Longitudinal Age and FAQ data. 
 Baseline Month 6 Year 1 Month 18 Year 2 Year 3 
NAge 402 388 360 170 316 217 
Age 75.4±6.7 75.9±6.7 76.5±6.7 76.6±7.0 77.6±6.5 78.6±6.4 
NFAQ 402 386 360 169 318 209 
FAQ 5.0±6.6 5.8±7.5 6.4±7.9 5.7±5.9 8.2±9.3 6.9±8.3 
 
N = number of subjects in sample 
Age and FAQ values represent mean ± standard deviation. 
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Figure 1. Predicted longitudinal FAQ scores from fixed effects models by 
diagnosis: Fixed effects include demographics and baseline clinical 
variables 
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Table 3. FDG ROIs surviving data reduction analysis using backward elimination GLM. 
Model: R
2
 = 0.60, p<0.0001 
Predictor β 95% CI for β 
 
P % Variance 
Accounted for 
Total Partial 
Baseline Diagnosis AD 7.63 6.4, 8.9 <0.0001 20.4 33.2 
MCI 0  
Posterior cingulate gyrus -14.14 -21.1, -7.1 <0.0001 2.1 4.7 
Orbitofrontal gyrus -22.88 -37.5, -8.3 0.002 1.2 2.8 
Frontal pole 32.88 16.4, 49.4 0.0001 2.0 4.6 
Lingual gyrus 8.22 1.1, 15.4 0.02 0.6 1.4 
Middle frontal gyrus -23.19 -34.5, -11.9 <0.0001 2.1 4.9 
Parahippocampal gyrus -17.95 -28.2, -7.8  0.0006 1.5 3.6 
 
AD (Alzheimer‟s disease), β (partial unstandardized regression coefficient estimate), CI (confidence 
interval), MCI (mild cognitive impairment) 
 
“%Variance Total” represents percent of total variance of FAQ uniquely associated with the indicated 
predictor (unbiased population estimate).  
 
“%Variance Partial” represents percent of variance of FAQ with portion associated with other predictors 
pre-removed, which is uniquely associated with the indicated predictor (unbiased population estimate). 
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Figure 2.  Localization of six FDG ROIs associated with total FAQ in one brain 
hemisphere.  (Top) lateral view of the hemisphere, (bottom) medial view 
of the hemisphere with significant FDG ROIs from data reduction 
analyses encircled in red.  The yellow asterisks on the inflated surface 
indicate the cortex around the perimeter of the central sulcus that has been 
„inflated‟ and is now visible.  Figure adapted from Desikan et al., 2006. 
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Cross Sectional Analyses 
Table 4 summarizes the results of the cross-sectional analysis.  The six FDG ROI 
discovered to have significant, within diagnosis group, relations to FAQ in the 
preliminary screening analysis reported above were included in the cross sectional 
analysis as described in the Methods section.  Following the second tier backward 
elimination, significant interactions were found for diagnosis with posterior cingulate 
(p<0.0001) and parahippocampal (p=0.0008) FDG hypometabolism.  The diagnostic 
interactions with the posterior cingulate and parahippocampal regions showed a steeper 
decline in IADL performance as FDG metabolism decreased for the AD dementia group 
relative to the MCI group, and the MCI group relative to the CN group (see Figure 3A 
and 3B). 
Main effects were found for orbitofrontal (p=0.009, Figure 3C) and middle frontal 
(p=0.003, Figure 3D) FDG hypometabolism in the expected negative direction with FAQ 
scores increasing as FDG metabolism decreased.  Interestingly, while the univariate 
unadjusted relationship for frontal pole FDG hypometabolism parallelled the negative 
direction found with the other FDG ROI main effects, this region demonstrated 
multicollinearity when adjusted to eliminate other covariates, excluding diagnosis.  That 
is, frontal pole FDG hypometabolism showed a positive partialed relation to baseline 
FAQ, likely due to its high positive correlations with some of the other FDG ROIs in the 
model, see Figures 3E and 3F (Figure 3E demonstrates the unadjusted FDG values with 
the negative relation and Figure 3F demonstrates the adjusted FDG values with the 
positive relation). 
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Additionally, significant relations were found for the covariates digit symbol and 
NPI-Q apathy item in expected directions (negative and positive, respectively).  The 
model as a whole accounted for 71 percent of the variance of FAQ and residuals 
conformed reasonably to assumptions (Table 4).    
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Table 4. Cross-sectional GLM of the association between baseline FAQ and regional 
FDG metabolism and covariates, displaying predictors retained in the final model after 
backward elimination. 
Model: R
2
=0.71, p<0.0001 
Predictor β  95% CI for β 
 
p % Variance 
Accounted for 
Total Partial 
Baseline Diagnosis AD 60.4 44.92, 75.89 <0.0001 5.2 14.7 
MCI 19.1 5.09, 33.03 
CN 0  
Posterior Cingulate x 
Diagnosis 
AD -28.62 -41.18, -16.07 <0.0001 1.5 4.6 
MCI -8.64 -19.05, 1.77 
CN 0  
Parahippocampus x 
Diagnosis 
AD -31.91 -49.77, -14.04 0.0008 0.9 3.0 
MCI -10.32 -27.19, 6.54 
CN 0  
Orbitofrontal -13.86 -24.28, -3.43 0.009 0.4 1.4 
Frontal pole 16.34 4.38, 28.29 0.008 0.5 1.5 
Middle frontal -12.81 -21.32, -4.30 0.003 0.6 1.9 
Digit Symbol -0.04 -0.08, -0.01 0.02 0.3 1.1 
NPI-Q apathy 1.68 1.02, 2.33 <0.0001 1.8 5.7 
 
AD (Alzheimer‟s disease), β (partial unstandardized regression coefficient estimate), CI (confidence 
interval), CN (clinically normal elderly), MCI (mild cognitive impairment), NPI-Q (Neuropsychiatric 
Inventory brief questionnaire form), „x‟ indicates an interaction,  
 
 “%Variance Total” represents percent of total variance of FAQ uniquely associated with the indicated 
predictor (unbiased population estimate), “%Variance Partial” represents percent of variance of FAQ with 
portion associated with other predictors pre-removed, which is uniquely associated with the indicated 
predictor (unbiased population estimate). 
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Figure 3. Cross-sectional graphs for predictor FDG ROI and baseline FAQ.
 Predictors including the indicated FDG ROI, diagnosis and the
 interaction of the indicated FDG ROI with diagnosis, if applicable. 
 The coefficient estimates were similar to those in the full model.  
 
 
 
3A 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Diagnosis 
Lines = predicted FAQ scores  
Symbols = actual FAQ scores  
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Longitudinal Analyses 
  Table 5 summarizes the results of the mixed effects longitudinal analysis.   The 
mixed effects backward elimination model resulted in a significant interaction for both 
posterior cingulate (p=0.004) and middle frontal (p=0.0005) FDG hypometabolism with 
time whereby individuals with lower baseline FAQ scores demonstrated worsening IADL 
impairment with increasing FAQ scores over time.  The faster trajectory of deterioration 
in FAQ scores for these FDG-ROI is depicted for each population across the AD 
spectrum in Figure 4.  The circles indicate when posterior cingulate gyrus FDG 
metabolism is one standard deviation below its mean SUV, while the squares indicate 
when it is one standard deviation above its mean SUV.  The solid blue lines are where 
middle frontal gyrus FDG metabolism is one standard deviation below its mean SUV and 
the dashed red lines indicate when it is one standard deviation above its mean SUV.  All 
other covariates were set at their grand means or illustrative values and included sex set 
to female, the number of APOE4 alleles set to 1, NPI-Q apathy score set to 1, baseline 
FAQ score set to 5, and RAVLT total learning score set to 32.  Low FDG metabolism in 
the posterior cingulate and middle frontal regions varied with the highest FAQ scores as 
represented by the uppermost line (solid blue line with circles). 
A counter-intuitive finding was a significant partialed interaction of the 
orbitofrontal FDG metabolism with time whereby higher values of FDG metabolism for 
the orbitofrontal cortex were significantly associated with faster deterioration (increasing 
FAQ scores).  This finding was possibly suggestive of multicollinearity due to moderate 
 26 
positive correlations of orbitofrontal cortex with the posterior cingulate gyrus and with 
the middle frontal gyrus.   
Also seen were significant effects for FAQ in the expected direction for APOE4 
(positive), RAVLT total learning (negative), NPI-Q Apathy (positive), baseline FAQ 
(positive), sex (female higher), and interactions of diagnosis with time such that the AD 
and MCI group deteriorated faster than did the CN group.  The longitudinal interactions 
between diagnosis and time are explained by years of study participation; as time in study 
increases, a duration of time over which to observe disease progression follows.  This 
trend is illustrated by the higher positive slopes seen in Figures 4B and 4C as compared 
to Figure 4A over the study‟s three years.  The percent variance accounted for by the 
overall model fixed effects was 75% and when including random terms 95%.  The 
residuals reasonably conformed to assumptions (Table 5).        
  
 27 
Table 5. Longitudinal mixed effects model of the association of FAQ over time to 
baseline regional FDG metabolism and covariates, displaying predictors retained in the 
final model after backward elimination. 
Model: R
2
=0.75 for fixed effects, p<0.0001; R
2
=0.95 including random terms, p<0.0001 
Predictor β 95% CI for β  P 
Time in study (years) 5.58 0.95, 10.2 0.02 
Baseline Diagnosis x time AD 1.57 0.68, 2.47 0.05 
MCI 1.64 1.04, 2.25  
CN  0   
RAVLT total learning -0.05 -0.09, -0.02 0.01 
APOE4 0.52 0.05, 1.00 0.03 
NPI-Q apathy 0.60 0.01, 1.18 0.005 
Posterior cingulate gyrus x time -4.80 -8.10, -1.51 0.004 
Orbitofrontal cortex x time  8.42 3.64, 13.20 0.001 
Middle frontal gyrus x time -7.67 -11.95, -3.39 0.001 
Posterior cingulate gyrus  2.00 -3.00, 7.00 0.43 
Orbitofrontal cortex -5.72 -12.6, 1.15 0.10 
Middle frontal gyrus  1.66 -4.55, 7.86 0.60 
Baseline FAQ 0.79 0.71, 0.87 <0.0001 
Sex Female 0.67 0.02, 1.33 0.04 
Male 0  
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Figure 4.   Predicted FAQ scores from fixed effects longitudinal model across time
 for posterior cingulate and middle frontal regions by diagnostic groups:
 CN (A), MCI (B), AD dementia (C).        
 
 
 
 
A 
 
 
 
 
 29 
 
 
 
B 
 
 
 
 
 
 
 30 
 
 
 
C 
 
 
 
 
 
 31 
DISCUSSION 
This data-driven analysis sought to characterize the relationship between regional 
FDG metabolism and IADL both cross-sectionally and longitudinally across the AD 
spectrum in CN, MCI, and mild AD dementia subjects.  Our results suggest that frontal 
and medial parietal synaptic dysfunction relate to functional decline at baseline and over 
time across the AD spectrum independent of demographics, APOE4 carrier status, 
memory and executive function performance, and behavioral factors. 
The cross-sectional results of our study suggest that orbitofrontal and middle 
frontal FDG hypometabolism significantly associates with greater IADL impairment, 
independent of diagnosis at baseline, while there were significant interactions for FDG 
posterior cingulate and parahippocampal hypometabolism with diagnosis illustrated by 
the steeper decline in IADL performance (increasing FAQ scores) as metabolism 
decreased for the AD dementia group relative to the MCI group, and the MCI group 
relative to the CN group.  Salmon et al. demonstrated an association between IADL 
impairment and inferior temporal, inferior parietal, and superior occipital 
hypometabolism in patients with mild to moderate AD dementia in a cross-sectional 
study using FDG PET (Salmon et al., 2005).  The cross-sectional results of the current 
study are in partial agreement with inferior temporal hypometabolism findings, as the 
parahippocampal gyrus  is associated with the temporal cortex, see Figure 1.  
The longitudinal analysis showed that baseline middle frontal and posterior 
cingulate FDG hypometabolism were significantly associated with a greater rate of 
increase in IADL impairment over time and across the AD spectrum.  In their seminal 
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work using FDG-PET to assess the relationship of typical AD hypometabolic patterns 
with cognitive and functional impairments in the same database used here (ADNI), 
Landau et al. showed that a priori selected patterns of baseline FDG-ROI 
hypometabolism can be predictive of future increases in FAQ score indicative of IADL 
decline (Landau et al., 2011).  Using a composite of FDG-ROI commonly accepted to be 
typical of AD dementia hypometabolism, they predicted longitudinal functional decline 
in MCI and mild AD dementia.  Similarly, our results suggest a faster trajectory of 
decline in IADL performance over time across the AD spectrum.  Individuals with lower 
baseline FAQ scores demonstrated worsening IADL impairment with increasing FAQ 
scores over time. 
Additionally, there was regional overlap and differences between the FDG ROI 
determined to have significant associations with FAQ in both Landau et al. and our study.  
The a priori selected composite FDG-ROI employed by Landau et al. included the 
angular gyri of the lateral parietal lobe, the temporal gyri of the temporal lobe as well as 
the posterior cingulate gyrus, which demonstrated a significant interaction with FAQ over 
time in our analysis also.  In our study, IADL deterioration was predicted by specific 
cortical regions that were determined through multivariate analyses to be significantly 
associated with FAQ.  We showed a similar association with posterior cingulate and 
parahippocampus, which is part of the temporal gyri included in the composite employed 
by Landau et al.  However, we also demonstrated associations with frontal regions 
(middle frontal and orbitofrontal), which were not included in the Landau composite 
since they are not generally considered to be highly typical of AD-related  
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hypometabolism.  Therefore, our data-driven approach, allowed for a more in-depth 
localization of IADL impairment, reinforcing the cortical regional localization of 
progressive functional impairment in the AD spectrum. 
The preliminary data reduction from thirty-five to six FDG ROI allowed the data 
to drive the localization of IADL impairment, and subsequently allowed for the most 
critical ROI to be identified.  This approach highlights the advantages of the data driven 
method over the more commonly used standardized atlases or voxel-based methods for 
region identification.  Specifically, patterns of hypometabolism discernible in atlas-
derived subregions may be washed out when averaged across an entire atlas-derived ROI.  
Additionally, ROI identified using voxel-based methods have limited application to 
populations outside study samples because the precision of ROI locations and their 
variance are directly influenced by the subjects and data processing methods. However, 
FDG-ROI may not fully encompass significant regions of declining glucose metabolism, 
which are captured in voxel-based analyses (Landau et al., 2011).  Together the use of 
data-derived FDG-ROI and a mixed effects longitudinal model allows the results to be 
more readily adaptable to patient populations. 
The use of a mixed effects longitudinal model is favorable for extrapolating 
results beyond the study sample.  By taking into account fixed and random effects within 
the model, implication of results from the model are not limited to fixed-subject sample.  
In order to understand the significance of each contributing predictor in our mixed effects 
longitudinal analysis, it was necessary to account for the fixed and random effects when 
designing the model.  For example, the longitudinal analysis included years in study to 
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control for multiple time points for data collection from years in study, the baseline FAQ 
covariate and its interaction with time to control for changes in FAQ score over time, the 
interaction of baseline diagnosis with time to control for change in diagnosis over time, 
as well as the FDG metabolism patterns for each of the six FDG ROI and each of their 
interactions with time to control for changes in FDG metabolism over time.   
This study features some limitations. The ADNI sample is not representative of 
the general population because the subjects are carefully selected to have limited general 
health issues, psychiatric conditions, and cerebrovascular disease. Moreover, the subjects 
were highly intelligent premorbidly and had a high proportion of APOE4 carriers. 
However, we adjusted for these elements in all analyses. Moreover, this sample 
resembles that of most AD spectrum clinical trials, making it easier to compare the 
results to clinical trial outcomes.  
The IADL scale used in these analyses, the FAQ, has been shown to be a sensitive 
measure for differentiating between CN, MCI, and mild AD dementia, but nearly all CN 
subjects have a score of 0 at baseline, representing a major floor effect (Marshall et al., 
2011 and Morris, 2012).  Therefore, the cross-sectional results were driven by the MCI 
and AD dementia groups. However, the longitudinal results were significant across all 
diagnostic groups indicating that the FAQ is sensitive to the development of functional 
decline over time even in CN subjects.  
One drawback to the data-driven regression models used in these analyses is the 
instances of multicollinearity in which counter-intuitive findings may falsely indicate the 
direction of an association (positive vs. negative).  Instances of multicollinearity were 
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observed cross-sectionally for the main effect of frontal pole FDG hypometabolism with 
baseline FAQ and longitudinally with orbitofrontal FDG hypometabolism and FAQ 
decline in this study.  In each case, the univariate unadjusted relationship was the reverse 
of the expected FDG ROI metabolism direction and may have been due to postive inter-
correlations between FDG ROI.   However, since significance tests run on the study 
results encompass numerous image pixels and mean SUV of the ROI and maximum pixel 
SUV are determined when generating FDG ROI, positive inter-correlations are expected 
and results are inherently conservative (Shankar et al., 2006; Locascio et al., 1997).  In 
their study of time series analysis using functional magnetic resonance brain imaging, 
Locascio et al. determined possible sources of positive correlation as attributable to 
physiologically based associations, close spatial proximity of pixels, image smoothing, or 
image resolution that is finer than areas of (non–task-related) activation (Locascio et al, 
1997).  
In conclusion, posterior cingulate, parahippocampal, orbitofrontal and middle 
frontal FDG hypometabolism are associated with IADL impairment in mild AD dementia 
cross-sectionally, while baseline posterior cingulate and middle frontal FDG 
hypometabolism predict worsening IADL impairment over time across the AD spectrum.  
These results demonstrate the association between patterns of regional FDG 
hypometabolism and complex daily functioning decline in early AD, and subsequently 
reinforce the importance of measuring IADL impairment throughout the course of AD 
progression.  
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